NASA awards $3.1M grant to continue studying stem cells aboard International Space Station

The National Stem Cell Foundation (NSCF) has received a $3.1 million grant from NASA to further its research on neurodegenerative diseases aboard the International Space Station (ISS). This funding will support additional ground research and facilitate three more missions to the ISS through 2027.

The NSCF reports that the award will allow additional ground research and another three missions to the ISS through 2027.

Kentucky Senate President Robert Stivers stated that Kentucky is matching 10% of the grant, or $300,000, indicating the state’s commitment to investing in the present and future.

Dr. Paula Grisanti, with NSCF, mentioned that their research focuses on diseases such as Parkinson’s and Multiple Sclerosis. “In space, you can see these cells talking to each other in a way that’s not possible on Earth,” said Dr. Grisanti.

She explained that they are able to study these cells using brain organoids, which are 3-D replicas of a brain made from cells of individuals with Parkinson’s or MS. “And that is opening the door to new biomarker discovery, new cell and gene therapies for these diseases that don’t currently exist and it is mapping a place for Kentucky at the forefront of space-based innovation,” said Grisanti. She added that their upcoming missions will include organoids from individuals with Alzheimer’s disease.

Mackenzie Wallace, Director of Public Policy for the Alzheimer’s Association, expressed excitement about this level of innovation, especially during a time when Alzheimer’s and Dementia research is rapidly advancing. She noted that while this research may not provide a cure for those currently affected by the disease, it remains promising. “They’re thinking about their children, their grandchildren and their great-grandchildren and what that may mean for them,” said Wallace. “That we may actually be getting to a cure someday and that in and of itself I think gives people a lot of hope.”

If you found this post helpful, would you mind sharing it? ⬇️ 

Related:

The company has emerged from stealth mode with a new $21 million Series A tranche (bringing total funding to $42 million), appointed Ron Cohen, M.D. as CEO, and reported early Phase 1b/2a Parkinson’s neuron replacement therapy data showing motor improvements
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s disease.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Stemchymal's CDMO has been selected, while the company seeks conditional approval in both Japan and Taiwan following Phase II results.
South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson's.

The Latest:

This is part of J&J's $55B investment in US manufacturing over the next few years.
The company is developing autologous cell therapies for fecal and urinary incontinence tied to weakened sphincter muscles.
ENCell's umbilical cord-derived mesenchymal stem cell therapy candidate EN001 received FDA orphan drug designation for Duchenne muscular dystrophy, marking its second designation after Charcot-Marie-Tooth disease and positioning it as a potential platform therapy for rare neuromuscular diseases.
Arizona lawmakers are advancing SB 1214, a bill that would allow certain non-FDA-approved stem cell and birth tissue therapies, with limitations.
They've completed enrollment of 99 patients across 15 U.S. sites in its Phase 2 trial evaluating BRTX-100, a mesenchymal stem cell therapy for chronic lumbar disc disease.
Zemcelpro (dorocubicel) is designed to support blood and immune system recovery after myeloablative conditioning in patients with hematologic diseases.
A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
GwoXi’s FDA filing aims to support cell therapy and exosome developers with a standardized, traceable stem cell source.
The lipid microbubble platform aims to enhance cell therapy manufacturing, adapted from its clinically validated ultrasound imaging tech.
The company says its platform may fundamentally change how cartilage loss and degenerative joint disease is treated globally.
Based on their results in Korea/Japan, they received a Phase 3 fast track in the USA, and hope to show true cartilage regeneration. Potentially historic moment for the industry coming.
The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.

Discover more from Regen Report

Subscribe now to keep reading and get access to the full archive.

Continue reading

Stay updated on Regenerative Medicine